Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BIND Biosciences, Inc. Receives $2M NIST ATP Award to Develop a High-Throughput Platform for Targeted Nanoparticle Engineering

Abstract:
BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing therapeutic targeted nanoparticles, announced today that it has received a three year $2,000,000 award from the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP) to further develop its platform for high-throughput formulation and selection of targeted nanoparticles.

BIND Biosciences, Inc. Receives $2M NIST ATP Award to Develop a High-Throughput Platform for Targeted Nanoparticle Engineering

Cambridge, MA | Posted on October 11th, 2007

"Given the extremely rigorous technical peer review involved in this competition, this award represents an important validation of BIND's technology platform," according to Dr. Stephen Zale, Vice President of Development at BIND and Principal Investigator of BIND's ATP project. He continued, "The ATP funding will accelerate industrialization of our high-throughput combinatorial platform for nanoparticle fabrication and screening that uniquely enables BIND to develop and manufacture targeted nanoparticle therapeutics optimized for a specific disease."

"We are delighted to have been selected by NIST for the ATP award and for their recognition of our platform's potential to create an entirely novel class of therapeutics based on optimally engineered targeted polymeric nanoparticles," said Glenn Batchelder, President and Chief Executive Officer of BIND. "We are fortunate to have Dr. Zale leading this program. Dr. Zale's two decades of pharmaceutical development experience includes a twelve year tenure at Alkermes where, as Vice President of Injectable Products, he helped build an extremely successful polymeric microparticle-based drug delivery platform which has led to the commercialization of important products such as Risperdal ConstaTM and VivitrolTM."

The NIST Advanced Technology Program selects the most promising early stage technologies with the potential to create fundamental paradigm shifts in their respective spaces. Of the hundreds of applicants for this year's ATP NIST program, less than ten percent were awarded contracts. ATP's early stage support has dramatically accelerated the development of many innovative technologies resulting in long term commercial success and delivering far reaching societal benefits.

####

About BIND Biosciences, Inc.
BIND Biosciences is a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles. The company’s product-platform leverages the convergence of polymeric biomaterials, nanoparticle engineering and combinatorial synthesis to uniquely enable BIND to design and optimize targeted nanoparticle therapeutics for specific indications. BIND’s technology concentrates drug at the intended site of action while minimizing systemic exposure, thereby improving efficacy and reducing off-target effects. The company’s platform is broadly applicable across therapeutic areas with the initial product development efforts focused in cancer and cardiovascular disease. The company anticipates initiating clinical trials for their first product in 2009.

BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer, MIT Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Assistant Professor of Anesthesiology. Backed by leading venture capital firms, Flagship Ventures and Polaris Venture Partners, the company has licensed a large patent estate covering these technologies on a worldwide exclusive basis from MIT and Brigham and Women’s Hospital – Harvard Medical School.

For more information, please click here

Contacts:
BIND Biosciences, Inc.
Glenn Batchelder, 617-491-3400
President and CEO

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Govt.-Legislation/Regulation/Funding/Policy

Programmable materials find strength in molecular repetition May 23rd, 2016

Rice de-icer gains anti-icing properties: Dual-function, graphene-based material good for aircraft, extreme environments May 23rd, 2016

ORNL demonstrates large-scale technique to produce quantum dots May 21st, 2016

Nanotubes are beacons in cancer-imaging technique: Rice University researchers use spectral triangulation to pinpoint location of tumors May 21st, 2016

Announcements

Physicists create first metamaterial with rewritable magnetic ordering May 23rd, 2016

Tiny packages may pack powerful treatment for brain tumors: Nanocarrier provides efficient delivery of chemotherapeutic drug May 23rd, 2016

Two-stage nanoparticle delivery of piperlongumine and TRAIL anti-cancer therapy May 23rd, 2016

Rice de-icer gains anti-icing properties: Dual-function, graphene-based material good for aircraft, extreme environments May 23rd, 2016

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Nanotubes are beacons in cancer-imaging technique: Rice University researchers use spectral triangulation to pinpoint location of tumors May 21st, 2016

Unveiling the electron's motion in a carbon nanocoil: Development of a precise resistivity measurement system for quasi-one-dimensional nanomaterials using a focused ion beam May 16th, 2016

A better hologram for fraud protection and wearable optics: Nanotechnology improves holographic capabilities by encoding light polarization May 16th, 2016

Scientists take a major leap toward a 'perfect' quantum metamaterial: Berkeley Lab, UC Berkeley researchers lead study that uses trapped atoms in an artificial crystal of light May 13th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic